Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-10-09 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized and issued shares, share options, and other share-related movements for Zai Lab Limited. It includes data on share capital, share options exercised, lapsed, and granted, as well as confirmations related to securities issuance. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. It is a regulatory submission about share capital and share movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content aligns with disclosures about share capital changes and share option schemes, which fits the category of Share Issue/Capital Change filings.
2023-10-09 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of share options and restricted share units under the 2022 Equity Incentive Plan. It details the number of options and restricted share units granted, the vesting periods, exercise prices, and other terms related to the equity incentive plan. The announcement references compliance with listing rules and provides definitions related to the equity plan. There is no financial statement, quarterly or annual report, nor is this a transcript, audit report, or legal proceeding. The content focuses on the issuance of share options and restricted shares, which is a capital change event. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is over 10,000 characters and contains detailed information about the share grants, not just a brief notice or a report publication announcement.
2023-10-05 English
2023 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 Interim Report' and contains detailed financial statements such as unaudited condensed consolidated balance sheets, statements of operations, comprehensive loss, shareholders' equity, and cash flows. It includes management discussion and analysis, forward-looking statements, and recent developments related to the company's commercial products and clinical trials. The presence of unaudited condensed consolidated financial statements and substantive financial data for a period shorter than a full fiscal year clearly indicates this is a comprehensive interim or quarterly report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-09-29 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS AND CLARIFICATION ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of share options and restricted share units under the 2022 Equity Incentive Plan. It details the number of options and restricted share units granted, the vesting periods, exercise prices, and clarifies a previous announcement's closing price. The document is regulatory in nature, related to equity incentive grants to employees, and includes compliance with listing rules. It is not a full financial report, earnings release, or management discussion. It is also not a proxy solicitation or AGM material. The content fits the category of a Capital/Financing Update as it relates to share option grants and equity incentive plans, which affect the company's capital structure and employee compensation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2023-09-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities for Zai Lab Limited, including authorized and issued share capital, share options, awards, and confirmations related to share issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes, share options exercised, shares issued, and confirmations of compliance with listing requirements. There is no financial performance data, earnings information, or management discussion. The document is not an announcement of a report but a regulatory submission detailing share capital movements and confirmations. This fits the category of Share Issue/Capital Change (SHA), as it reports on new share issues, share options exercised, and related capital changes.
2023-09-06 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023' and contains detailed unaudited condensed consolidated financial statements including balance sheets, statements of operations, comprehensive loss, shareholders' equity, and cash flows for the six-month period ended June 30, 2023. It also includes notes to the financial statements and references compliance with U.S. GAAP and HK Listing Rules for interim financial reporting. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report.
2023-08-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.